Cohance Lifesciences Board of Directors

Get the latest insights into the leadership at Cohance Lifesciences. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Annaswamy Vaidheesh Executive Chairperson
Dr. V Prasada Raju Managing Director
Mr. Pankaj Patwari Non Executive Director
Ms. Shweta Jalan Non Executive Director
Ms. Matangi Gowrishankar Independent Director
Mr. Vinod Rao Independent Director
Mr. K G Ananthakrishnan Independent Director
Mr. Pravin Rao Udhyavara Bhadya Independent Director

Cohance Lifesciences Share price

COHANCE

899.3

5.70 (-0.63%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:44 IST
BUYSELL
Today's High

913.95

Today's Low

892.75

52 Week Low

856.30

52 Week High

1360.00

The current prices are delayed, login to your account for live prices

Cohance Lifesciences FAQs

The board at Cohance Lifesciences consists of experienced professionals, including Mr. Annaswamy Vaidheesh , Dr. V Prasada Raju , and others, overseeing the company’s strategic and corporate governance.

Directors at Cohance Lifesciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Annaswamy Vaidheesh is the current chairman at Cohance Lifesciences.

Executive directors at Cohance Lifesciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Cohance Lifesciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Cohance Lifesciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.